双重抗血小板治疗同时抗凝:三联治疗的现状。

Haris Patail, Tanya Sharma, Atul D Bali, Ameesh Isath, Wilbert S Aronow, Syed Abbas Haidry
{"title":"双重抗血小板治疗同时抗凝:三联治疗的现状。","authors":"Haris Patail,&nbsp;Tanya Sharma,&nbsp;Atul D Bali,&nbsp;Ameesh Isath,&nbsp;Wilbert S Aronow,&nbsp;Syed Abbas Haidry","doi":"10.5114/amsad/161172","DOIUrl":null,"url":null,"abstract":"<p><p>Anticoagulation and antiplatelet therapy are individually mainstays of treatment for multiple cardiovascular conditions. Antiplatelet therapy, most commonly with dual agents, is vital in the setting of coronary artery disease with acute coronary syndrome requiring percutaneous coronary intervention to prevent in-stent complications. A multitude of cardiovascular conditions with increased thromboembolic risk also require anticoagulation, including atrial fibrillation, venous or arterial thrombosis, and prosthetic heart valves to name a few. There is often an overlap in comorbidities as our patient population ages and becomes more complex, frequently necessitating a combination of both anticoagulation and antiplatelet agents, known as \"triple therapy\". To reduce or treat thromboembolic disease states as well as reduce platelet aggregation for coronary stent protection, many patients are placed at an increased bleeding risk without compelling evidence of reduction in major adverse cardiac events. With this comprehensive review of the existing literature, we aim to analyse different strategies and durations of triple therapy medication regimens.</p>","PeriodicalId":8317,"journal":{"name":"Archives of Medical Sciences. Atherosclerotic Diseases","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bc/e6/AMS-AD-8-161172.PMC10161787.pdf","citationCount":"0","resultStr":"{\"title\":\"Dual antiplatelet therapy with concomitant anticoagulation: current perspectives on triple therapy.\",\"authors\":\"Haris Patail,&nbsp;Tanya Sharma,&nbsp;Atul D Bali,&nbsp;Ameesh Isath,&nbsp;Wilbert S Aronow,&nbsp;Syed Abbas Haidry\",\"doi\":\"10.5114/amsad/161172\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Anticoagulation and antiplatelet therapy are individually mainstays of treatment for multiple cardiovascular conditions. Antiplatelet therapy, most commonly with dual agents, is vital in the setting of coronary artery disease with acute coronary syndrome requiring percutaneous coronary intervention to prevent in-stent complications. A multitude of cardiovascular conditions with increased thromboembolic risk also require anticoagulation, including atrial fibrillation, venous or arterial thrombosis, and prosthetic heart valves to name a few. There is often an overlap in comorbidities as our patient population ages and becomes more complex, frequently necessitating a combination of both anticoagulation and antiplatelet agents, known as \\\"triple therapy\\\". To reduce or treat thromboembolic disease states as well as reduce platelet aggregation for coronary stent protection, many patients are placed at an increased bleeding risk without compelling evidence of reduction in major adverse cardiac events. With this comprehensive review of the existing literature, we aim to analyse different strategies and durations of triple therapy medication regimens.</p>\",\"PeriodicalId\":8317,\"journal\":{\"name\":\"Archives of Medical Sciences. Atherosclerotic Diseases\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bc/e6/AMS-AD-8-161172.PMC10161787.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of Medical Sciences. Atherosclerotic Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/amsad/161172\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Medical Sciences. Atherosclerotic Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/amsad/161172","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

抗凝和抗血小板治疗是治疗多种心血管疾病的主要方法。抗血小板治疗,最常见的是双药治疗,对于需要经皮冠状动脉介入治疗以预防支架内并发症的冠状动脉疾病合并急性冠状动脉综合征至关重要。许多增加血栓栓塞风险的心血管疾病也需要抗凝治疗,包括心房颤动、静脉或动脉血栓形成和人工心脏瓣膜等。随着患者年龄的增长和病情的复杂化,合并症往往会出现重叠,这往往需要抗凝和抗血小板药物的联合治疗,即所谓的“三联治疗”。为了减少或治疗血栓栓塞性疾病状态以及减少血小板聚集以保护冠状动脉支架,许多患者处于出血风险增加的状态,而没有令人信服的证据表明主要不良心脏事件减少。通过对现有文献的全面回顾,我们旨在分析三联疗法的不同策略和持续时间。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Dual antiplatelet therapy with concomitant anticoagulation: current perspectives on triple therapy.

Dual antiplatelet therapy with concomitant anticoagulation: current perspectives on triple therapy.

Anticoagulation and antiplatelet therapy are individually mainstays of treatment for multiple cardiovascular conditions. Antiplatelet therapy, most commonly with dual agents, is vital in the setting of coronary artery disease with acute coronary syndrome requiring percutaneous coronary intervention to prevent in-stent complications. A multitude of cardiovascular conditions with increased thromboembolic risk also require anticoagulation, including atrial fibrillation, venous or arterial thrombosis, and prosthetic heart valves to name a few. There is often an overlap in comorbidities as our patient population ages and becomes more complex, frequently necessitating a combination of both anticoagulation and antiplatelet agents, known as "triple therapy". To reduce or treat thromboembolic disease states as well as reduce platelet aggregation for coronary stent protection, many patients are placed at an increased bleeding risk without compelling evidence of reduction in major adverse cardiac events. With this comprehensive review of the existing literature, we aim to analyse different strategies and durations of triple therapy medication regimens.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信